Molecular measurements of treatment response—clinical applications.
| Application . | Action . |
|---|---|
| Abbreviations: MRD, minimal residual disease; HSCT, hematopoietic stem cell transplantation; DLI, donor lymphocyte infusion | |
| Detect poor early treatment response | Treatment intensification |
| Detect good early treatment response | Treatment deintensification |
| Detect relapse | Treatment intensification; prepare for HSCT |
| Measure MRD before HSCT | Optimize timing of HSCT |
| Measure MRD after HSCT | Modulate immunosuppression, DLI, etc. |
| Measure MRD at the end of experimental remission induction protocol | Apply MRD-based stopping rule |
| Evaluate novel anti-leukemic agents | Novel design of Phase II studies |
| Application . | Action . |
|---|---|
| Abbreviations: MRD, minimal residual disease; HSCT, hematopoietic stem cell transplantation; DLI, donor lymphocyte infusion | |
| Detect poor early treatment response | Treatment intensification |
| Detect good early treatment response | Treatment deintensification |
| Detect relapse | Treatment intensification; prepare for HSCT |
| Measure MRD before HSCT | Optimize timing of HSCT |
| Measure MRD after HSCT | Modulate immunosuppression, DLI, etc. |
| Measure MRD at the end of experimental remission induction protocol | Apply MRD-based stopping rule |
| Evaluate novel anti-leukemic agents | Novel design of Phase II studies |